Pfizer has appointed Chris Boshoff, its current chief oncology officer and executive vice president, as chief scientific officer and president, research and development (R&D).
Boshoff, who will be taking on the role at the beginning of January, will remain a member of Pfizer’s executive leadership team and will lead R&D across all of the company’s therapeutic areas, including oncology.
He has spent more than a decade at Pfizer, previously serving as chief development officer for oncology and rare disease, as well as head of development Japan across all therapeutic areas.
Boshoff was also previously founding director of the University College London Cancer Institute, and is an elected fellow of the UK Academy of Medical Sciences.
Albert Bourla, chairman and chief executive officer at Pfizer, said: “Chris has a compelling vision for the future of R&D at Pfizer and deep knowledge of our entire pipeline and research and development organisation that positions him well to succeed. He has an impressive record of building strong teams and delivering numerous breakthrough medicines.”
Commenting on his latest venture, Boshoff said: “I am honoured to be succeeding Mikael [Dolsten] and to be taking on leadership of a combined R&D organisation… I look forward to working even more closely with Albert, our executive leadership team, and our entire R&D organisation to take Pfizer’s pipeline and productivity to the next level.”